FQ
ECYT

First Quadrant’s Endocyte, Inc. Common Stock ECYT Stock Holding History

First Quadrant’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,900
Closed -$79K – 835
2013
Q3 		$79K Buy
5,900
+2,900
+97% +$45.8K ﹤0.01% 631
2013
Q2 		$39K Buy
+3,000
New +$40.5K ﹤0.01% 707

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

First Quadrant's ECYT Position: Q4 2013 in Review

First Quadrant sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2013, closing a stake of 5,900 shares — an estimated $79K sold.

First Quadrant first reported a position in ECYT in Q2 2013 and held it in 2 quarters. The position peaked at $79K in Q3 2013. 90 funds tracked by Wall St. Rank hold ECYT as of Q4 2013.

  • First Quadrant reported no remaining Endocyte, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • First Quadrant sold 5,900 Endocyte, Inc. Common Stock shares in Q4 2013, an estimated $79K.
  • First Quadrant first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • First Quadrant's Endocyte, Inc. Common Stock position peaked at $79K in Q3 2013.
  • 90 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2013.

Based on First Quadrant's 13F filing for Q4 2013, filed 29 Jan 2014.